The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 28591512 |
114 |
Discovery of a Highly Selective Tankyrase Inhibitor Displaying Growth Inhibition Effects against a Diverse Range of Tumor Derived Cell Lines. |
Glaxosmithkline |
| 28169167 |
137 |
Design and synthesis of a novel series of 4-heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes asa7 nicotinic receptor agonists 2. Development of 4-heteroaryl SAR. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
| 27639361 |
88 |
Synthesis and biological evaluation of novel hybrids of highly potent and selectivea4ß2-Nicotinic acetylcholine receptor (nAChR) partial agonists. |
University of Illinois At Chicago |
| 24901260 |
12 |
Recent developments in novel antidepressants targetinga4ß2-nicotinic acetylcholine receptors. |
University of Illinois At Chicago |
| 24050653 |
59 |
Derivatives of dibenzothiophene for positron emission tomography imaging ofa7-nicotinic acetylcholine receptors. |
The Johns Hopkins University School of Medicine |
| 24035337 |
10 |
2-Amino-6-chloro-3,4-dihydroquinazoline: A novel 5-HT3 receptor antagonist with antidepressant character. |
Virginia Commonwealth University |
| 23602445 |
23 |
An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'. |
Ucl School of Pharmacy |
| 20591663 |
23 |
Identification of novel alpha7 nAChR positive allosteric modulators with the use of pharmacophore in silico screening methods. |
Glaxosmithkline |
| 15686946 |
36 |
Halogenated and isosteric cytisine derivatives with increased affinity and functional activity at nicotinic acetylcholine receptors. |
National Institute of Diabetes and Digestive and Kidney Diseases |
| 22503453 |
59 |
The discovery of 2-fluoro-N-(3-fluoro-4-(5-((4-morpholinobutyl)amino)-1,3,4-oxadiazol-2-yl)phenyl)benzamide, a full agonist of the alpha-7 nicotinic acetylcholine receptor showing efficacy in the novel object recognition model of cognition enhancement. |
Glaxosmithkline |
| 22503248 |
61 |
Identification of a series of 1,3,4-oxadiazol-2-amines as potent alpha-7 agonists with efficacy in the novel object recognition model of cognition. |
Glaxosmithkline |
| 8765504 |
34 |
(S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): a novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors. |
Sibia Neurosciences |
| 11212100 |
27 |
The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist. |
Astrazeneca |
| 21824774 |
17 |
Synthesis and biological activity of a novel class nicotinic acetylcholine receptors (nAChRs) ligands structurally related to anatoxin-a. |
University of Ferrara |
| 20509659 |
182 |
Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. |
Barrow Neurological Institute |
| | 11 |
Novel 2-(2′-furo[3,2-b]pyridinyl) pyrrolidines: potent neuronal nicotinic acetylcholine receptor ligands |
TBA |
| 19208472 |
52 |
Gamma-lactams--a novel scaffold for highly potent and selective alpha 7 nicotinic acetylcholine receptor agonists. |
Novartis Institutes For Biomedical Research |
| 16821801 |
35 |
Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship. |
Pfizer |
Search and Browse
